SWK (NASDAQ:SWKH) Shares Down 4.1% – Should You Sell?

Shares of SWK Holdings Co. (NASDAQ:SWKH) were down 4.1% during mid-day trading on Friday . The company traded as low as $15.63 and last traded at $15.80. 67,931 shares traded hands during mid-day trading, an increase of 530% from the average daily volume of 10,786 shares. The stock had previously closed at $16.47.

SWK Trading Down 4.1 %

The stock has a 50-day simple moving average of $16.36 and a 200 day simple moving average of $16.80. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.11. The company has a market cap of $193.28 million, a price-to-earnings ratio of 16.99 and a beta of 0.35.

Hedge Funds Weigh In On SWK

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of SWK by 185.0% in the 3rd quarter. Barclays PLC now owns 4,461 shares of the company’s stock valued at $77,000 after buying an additional 2,896 shares during the period. Bank of New York Mellon Corp acquired a new stake in SWK in the second quarter valued at approximately $172,000. Dimensional Fund Advisors LP increased its position in shares of SWK by 85.7% in the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock valued at $511,000 after buying an additional 13,892 shares in the last quarter. SkyView Investment Advisors LLC raised its stake in shares of SWK by 7.7% during the 2nd quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock worth $529,000 after buying an additional 2,234 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of SWK during the 3rd quarter valued at approximately $589,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

SWK Company Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.